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The vaginal microbiota associates with the
regression of untreated cervical intraepithelial
neoplasia 2 lesions
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Emerging evidence suggests associations between the vaginal microbiota (VMB) composi-
tion, human papillomavirus (HPV) infection, and cervical intraepithelial neoplasia (CIN);
however, causal inference remains uncertain. Here, we use bacterial DNA sequencing from
serially collected vaginal samples from a cohort of 87 adolescent and young women aged
16–26 years with histologically confirmed, untreated CIN2 lesions to determine whether VMB
composition affects rates of regression over 24 months. We show that women with a Lac-
tobacillus-dominant microbiome at baseline are more likely to have regressive disease at
12 months. Lactobacillus spp. depletion and presence of specific anaerobic taxa including
Megasphaera, Prevotella timonensis and Gardnerella vaginalis are associated with CIN2 per-
sistence and slower regression. These findings suggest that VMB composition may be a
future useful biomarker in predicting disease outcome and tailoring surveillance, whilst it may
offer rational targets for the development of new prevention and treatment strategies.
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Persistent infection with high-risk human papillomavirus(hrHPV) is causally associated with the development ofinvasive cervical cancer1. HPV infection is common and the
lifetime risk of acquiring such an infection exceeds 80%2. The
majority of these infections however are cleared spontaneously
through an incompletely understood immune response3. A
fraction of women with HPV persistence go on to develop the
pre-invasive precursor, high-grade cervical intraepithelial neo-
plasia (CIN2 & 3)4. Cervical screening programmes are aimed at
secondary prevention of cervical cancer through the ability to
detect, surveil and treat CIN when necessary. Traditionally, his-
tological diagnosis of CIN2+ has been used as the cut-off to
proceed to treatment, whilst low-grade CIN (CIN1) is believed to
be a histological diagnosis of benign viral replication5.
CIN2 is often regarded as a heterogeneous disorder that can be
caused by both low- and high-risk HPV (hrHPV) subtypes with
various carcinogenic potential6,7. Despite current recommenda-
tions to treat histologically confirmed CIN2 lesions, immediate
surgical management is controversial due to the high rates of
regression cited by observational studies and adverse reproductive
sequelae of local treatment, specifically in younger women8,9.
Moscicki et al.10 reported a 68% rate of spontaneous regression in
95 adolescent and young adult women with histologically con-
firmed CIN2 that were conservatively managed at 4-month
intervals. A recent meta-analysis of 36 studies that enroled 3160
women reported a 50% rate of regression at 2 years and almost
60% when this was restricted to women under 30 years of age8.
Emerging evidence leads us to conclude that vaginal microbiota
(VMB) composition varies in women with hrHPV infections and
high-grade CIN11–15. We previously reported that increased CIN
disease severity is associated with decreasing relative abundance of
Lactobacillus spp.14, however, the cross-sectional nature of these
datasets did not permit exploration on the impact that that VMB
composition may have on clinical outcome of CIN and HPV
infection clearance11–14,16–20. In an earlier study by Brotman et al.11
serial sampling of women over the course of 16 weeks suggested that
Lactobacillus gasseri-dominant communities may promote clearance
of acute HPV infection. Although limited by statistical power, the
study highlighted the potential utility of longitudinal profiling to
examine temporal relationships between VMB and HPV infection.
Furthermore, recent studies have begun to examine the impact of the
VMB, HPV and cellular change on the metabolic profile, which
promotes many of the inflammatory and metabolic mechanisms
necessary for persistent viral infection and carcinogenesis21,22.
In this prospective longitudinal study of historically collected
samples, we investigate the vaginal microbiota composition in a
cohort of non-pregnant adolescent and young adult women aged
16–26 years, with histologically proven CIN2 managed con-
servatively over a 24-month period. The objective of the study is to
examine temporal relationships between VMB and the natural
history of CIN2 and determine whether VMB composition assessed
at baseline predicts outcomes at 12 and 24 months. We show that
women with a Lactobacillus-dominant microbiome at baseline are
more likely to have regressive disease at 12 months. Lactobacillus
spp. depletion and presence of specific anaerobic taxa including
Megasphaera, Prevotella timonensis and Gardnerella vaginalis are
associated with CIN2 persistence and slower regression. Our find-
ings suggest that VMB composition may be a future useful bio-
marker in predicting disease outcome and tailoring surveillance,
and in addition may provide rational strategies for the development
of targeted prevention and treatment methods.
Results
Patient cohort, characteristics and outcomes. Ninety-five
women with histologically confirmed CIN2 were recruited.
Eight women with missing baseline samples were excluded, giving
a total of 87 women and 573 samples included for the final
analysis. The mean follow-up period was 27.4 months (range
5.0–46.8 months). The mean number of biopsies during follow-
up period due to clinical indications was 1 (range 0–6). An exit
biopsy was offered to all patients who attended their final visit; 58
women (67%) consented to have a biopsy. Of the 87 women who
entered the study with histologically confirmed CIN2, 42 had
regressed by 12 months (48.3%) and the remaining 45 were
classified as non-regressors (51.7%). Nine patients were subse-
quently lost to follow-up before they regressed and were included
as ‘non-regression’ at 24 months (Fig. 1). At 24 months, 63
women had regressed (72.4%) and 24 had not (27.6%). Of the
non-regressors, only a small number progressed to CIN3; one
patient by 12 months, and a total of five by 24 months.
Patient characteristics at the baseline visit are detailed in
Table 1. The mean age was 20.5 (16.0–26.5), and the mean
number of sexual partners was 8 (refs. 1–35). One in four women
were smokers (24/87, 27.6%) and had previously been infected
with C. trachomatis (22/87, 25.3%). Almost half of them had been
previously pregnant (40/87, 46.0%), whereas 15% had ever
practiced anal intercourse (13/87). HPV status was known for
85 patients at time of CIN2 diagnosis (97.7%), of whom 6 were
HPV negative (6/85, 6.9%). Of the remaining 79 patients who
were HPV positive, 73 were positive for at least one high-risk
subtype (73/79, 85.8%). Thirty patients were HPV16 positive (30/
79, 37.9%) and eight were infected with HPV18 (8/79, 10.1%).
Twenty-eight women were infected with a single HPV subtypes
(28/79, 35.4%), and fifty-one were infected with multiple HPV
subtypes (51/79, 64.6%). There was no statistically significant
difference in these characteristics according to regression or non-
regression (Table 1).
Baseline vaginal microbiota composition and disease out-
comes. In total 2,627,778 reads were obtained from 573 samples
with an average number of reads per sample of 4586 and the
median read length of 370 bp after bar code removal. Following
removal of singletons and rare OTUs, a total of 160 taxa were
identified in the vaginal microbiota of the study cohort. To avoid
sequencing bias, operational taxonomic units (OTUs) were ran-
domly sub-sampled to the lowest read count of 885, providing a
minimum coverage of 98.7% for all samples. The top 20 taxa
accounted for 96.6% of the total sequence reads, and therefore
further analysis was restricted to the top 20 taxa, with the
remaining 140 taxa denoted as ‘other’. Hierarchical clustering of
genus level data for the whole cohort identified two major groups;
those with ≥81.6% Lactobacillus content which we categorised as
Lactobacillus-dominant and those with <54.2% Lactobacillus
content, categorised as Lactobacillus-depleted communities, and
these were observed in 65.5% (57/87) and 34.5% (30/87) of
samples at baseline, respectively (Fig. 2). Similar analyses were
performed at species level with hierarchical clustering analysis
identifying three of the previously described CST’s; CST I clas-
sified as ≥54.4% Lactobacillus crispatus content, CST III as
≥63.3% Lactobacillus iners content. Anything with <42.9% Lac-
tobacillus spp. content was classified as CST IV. CST III (L. iners-
dominant) was observed most commonly at baseline (36/87,
41.4%), followed by CST IV (Lactobacillus spp.-depleted, 30/87,
34.5%) and CST I (L. crispatus-dominant, 21/87, 24.1%) (Fig. 2).
CST II and CST V, dominated by L. gasseri and L. jensenii,
respectively, were not observed in any of these baseline samples,
but were identified in a small number of samples at subsequent
visits. VMB composition at genus or species level did not vary
significantly according to HPV positivity or subtype at baseline
(Supplementary Table 4).
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Hierarchical clustering analysis (HCA) using centroid cluster-
ing showed the VMB composition at genus level differs according
to whether women showed regression of disease (determined by
2× normal cytology/histology samples), or non-regression at
12 months (adjusted odds ratio (aOR) 3.56, 95% confidence
interval (CI) 1.31–9.60 (p= 0.012, χ2 test)), and at 24 months
(aOR 2.85, 95% CI 1.03–7.92 (p= 0.045, χ2 test)), when adjusted
for age, ethnicity, contraception, smoking, douching and HPV16
and 18 positivity (Figs. 2, 3 and Table 2). When the same analysis
was performed at species level, there was a significant difference
in clinical outcomes according to CST at 12 months (p= 0.0420,
χ2 test), with CST IV at baseline being associated with a higher
change of persistence at 12 (aOR 3.85, 95% CI 1.10–13.42, (p=
0.035, χ2 test)) and 24 months (aOR 4.25, 95% CI 0.98–18.50
(p= 0.054, Fisher’s exact test)) compared to women with CST I at
baseline (Figs. 2, 3 and Table 2). There was no significant
difference in variables that may impact on VMB composition,
such as contraception, douching, ethnicity, HPV status or
smoking, as further shown in Table 1.
The distribution of baseline VMB composition according to
clinical outcomes at 12 months is shown in Table 2 and Fig. 4.
Women with a Lactobacillus-dominant VMB at baseline were
almost twice as likely have regressed at the 12-month follow-up,
compared to those with Lactobacillus-depleted VMB (21/30,
70.0% vs 24/57, 42.1%; aOR 3.56, 95% CI 1.31–9.60 (p= 0.012, χ2
test)) (Table 2, Figs. 3, 4a, b). CST IV was significantly associated
with non-regression compared with women with CST I (aOR
3.85, 95% CI 1.10–13.42 (p= 0.035, χ2 test)). There was however
no significant difference in regression rates at 12 months when
comparing women with CST I and CST III (aOR 1.86, 95% CI
0.39–8.81 (p= 0.432, χ2 test)). Consistent with these findings,
bacterial richness, as determined by the number of species
observed (Sobs) was significantly higher in women who did not
regress compared to those who did (p= 0.0105, unpaired t-test),
with a trend towards greater diversity, assessed using the Inverse
Simpson index (p= 0.0641, unpaired t-test).
The baseline vaginal microbiota of the 45 women who had not
regressed at 12 months was characterised by an increased
abundance of Megasphaera unclassified (p= 0.00386, Welch’s t-
test, unadjusted), BVAB1 (p= 0.043, Welch’s t-test, unadjusted)
Prevotella timonensis (p= 0.015, Welch’s t-test, unadjusted) and
Gardnerella vaginalis (p= 0.036, Welch’s t-test, unadjusted)
compared to the 42 women who regressed by this timepoint,
although this did not stand up to multiple test correction, likely
due to sample size (Fig. 4d). LEfSe analysis identified Lactoba-
cillus spp. to be predictive of regression at 12 months whereas
non-regression was associated with enrichment of Prevotella,
Megasphaera, BVAB1, Sneathia and Atopobium species (Fig. 5).
A similar relationship was seen between Lactobacillus depletion
at baseline and non-regression at 24-month follow-up (aOR 2.85,
95% CI 1.03–7.92 (p= 0.045, χ2 test)) and with CST IV
overrepresentation at baseline (aOR 4.25, 95% CI 0.98–18.50
(p= 0.054, χ2 test)) (Table 2, Fig. 3, Supplementary Fig. 2a, b).
VMB richness at baseline was significantly greater in women with
non-regression at 24 months compared to those who regressed
(p= 0.0105, χ2 test) (Supplementary Fig. 2c, Supplementary
table 2). Four species found at baseline to be significantly
associated with non-regression at 12 months were again
associated with non-regression at 24 months; Prevotella timo-
nensis (p= 0.03, Welch’s t-test, unadjusted), Megasphaera
(unclassified) (p= 0.033, Welch’s t-test, unadjusted) and Gard-
nerella vaginalis (p= 0.037, Welch’s t-test, unadjusted), although
this did not stand up to multiple test correction, again, likely due
to sample size (Supplementary Fig. 2d).
Total cohort (n = 87)Time = 0 months
Time = 12 months
Time = 24 months
Non-regression
(n = 45)
Regression
(n = 42)
Non-regression
(n = 24)
Regression
(n = 63)
Regression
(n = 21)
Non-regression
(n = 35)
Non-regression
(n = 14)
Excluded (n = 10)
CIN3
(n = 4)
CIN3
(n = 4)
CIN3
(n = 1)
LFU
(n = 9)
Sub-group analysis
Fig. 1 Study cohort and timepoints. All patients entered the study at baseline with histologically confirmed CIN2. The results of follow-up histology and
cytology were assessed at 12 and 24 months to determine whether the individual had regressed (at least 2× normal histology or cytology) or not (non-
regression). By 12 months, 45 patients were classified as non-regressors. Of these, one patient had progressed to CIN3 and nine were subsequently lost to
follow-up, leaving 35 patients for a further subgroup analysis. The vaginal microbiome composition at this 12-month follow-up visit was then regarded to be
the ‘new baseline’, and the outcome from 12 to 24 months was then assessed. LFU lost to follow-up.
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Subgroup analysis of women who did or did not regress
between the 12- and 24-month follow-ups was next performed
(Supplementary table 1). Of the non-regressors at 12 months
(n= 45), one progressed to CIN3 and nine were lost to follow-
up, and these 10 participants were excluded, leaving 35 women
with ongoing disease who were included in the subgroup
analysis (Fig. 1, Supplementary Fig. 1). VMB composition at the
12-month appointment was used as the baseline comparator
against which outcomes at the 24-month follow-up were
measured (Table 2, Fig. 3, Supplementary Fig. 3). A trend in
higher rates of Lactobacillus depletion and CST IV were
associated with non-regression from 12 to 24 months, although
this was not statistically significant (Genus level analysis (aOR
3.06, 95% CI 0.54–17.14 (p= 0.202, χ2 test))), species level
analysis (aOR 4.94, 95% CI 0.26–94.86 (p= 0.29, Fisher’s exact
test)). There was no difference in richness or diversity
according to clinical outcomes between 12 and 24 months
(Supplementary Fig. 3c, Supplementary table 3). Anaerococcus
Table 1 Patient characteristics of 87 patients included in study cohort.
Non-regression at 12 months, n= 45 Regression at 12 months, n= 42 All, n= 87 p-value
Age, years 0.1951
Mean (SD, range) 20.1 (2.4, 16.0–24.9) 20.8 (2.6, 16.1–26.5) 20.5 (2.4, 16.0–26.5)
Ethnicity, n/N (%) 0.6112
Caucasian 17/45 (37.8) 20/42 (47.6) 37/87 (42.5)
Black 8/45 (28.9) 9/42 (21.4) 17/87 (19.5)
Latin 11/45 (24.4) 8/42 (19.0) 19/87 (21.9)
Other ethnicity 9/45 (8.9) 5/42 (11.9) 14/87 (16.1)
Smoking, n/N (%) 0.4808
Current smoker 14/45 (31.3) 10/42 (23.8) 24/87 (27.6)
Non-smoker 31/45 (68.9) 32/42 (76.2) 63/87 (72.4)
Weekly alcohol use, n/N (%) 1.000
Yes 1/45 (2.2) 0/42 (0) 1/87 (95.4)
No 44/45 (97.8) 42/42 (100.0) 86/87 (4.6)
Weekly drug use, n/N (%) 0.5415
Yes 5/45 (11.1) 7/42 (16.7) 12/87 (13.8)
No 40/45 (88.9) 35/42 (83.3) 75/87 (86.2)
Current/previous vaginal douching, n/N (%) 0.6337
Yes 13/45 (28.9) 10/42 (23.8) 23/87 (26.4)
No 32/45 (71.1) 32/42 (76.2) 64/87 (73.6)
Contraception, n/N (%) 0.6491
Nil 14/45 (31.1) 17/42 (40.5) 31/87 (35.6)
Contraceptive injection 8/45 (17.8) 7/42 (16.7) 15/87 (17.2)
Other oral combined hormonal contraception 23/45 (51.1) 18/42 (42.8) 41/87 (47.2)
Previous pregnancy, n/N (%) 0.6682
Yes 22/45 (48.9) 18/42 (42.9) 40/87 (46.0)
No 23/45 (51.1) 24/42 (57.1) 47/87 (54.0)
Number of sexual partners 0.5136
Mean (SD, range) 8 (8, 1–35) 7 (6, 2–25) 8 (7, 1–35)
Current sexual practice, n/N (%) 0.0971
Abstinence 32/45 (71.1) 28/42 (66.7) 60/87 (69.0)
Monogamous 9/45 (20.0) 4/42 (9.5) 13/87 (15.0)
Non-monogamous 4/45 (8.9) 10/42 (23.8) 14/87 (16.0)
History of anal intercourse, n/N (%) 0.7674
Yes 6/45 (13.3) 7/42 (16.7) 13/87 (15.0)
No 39/45 (86.7) 35/42 (83.3) 74/87 (85.0)
History of genital infections, n/N (%) 0.8195
Chlamydia trachomatis 8/45 (17.8) 14/42 (33.3) 22/87 (25) 0.1384
Neisseria gonorrhea 1/45 (2.2) 3/42 (7.1) 4/87 (5) 0.3493
Trichomonas vaginalis 2/45 (4.4) 1/42 (2.4) 3/87 (3) 1.000
Genital warts 5/45 (11.1) 5/42 (11.9) 10/87 (11) 1.000
Syphilis 0/45 (0) 0/42 (0) 0/87 (0) 1.000
Bacterial vaginosis 5/45 (11.1) 9/42 (21.4) 14/87 (16) 0.2475
Yeast infection 21/45 (46.7) 21/42 (50.0) 42/87 (48) 0.8313
HSV 2/45 (4.4) 3/42 (7.1) 5/87 (6) 0.6693
HIV 0/45 (0) 0/42 (0) 0/87 (0) 1.000
HPV status, n/N (%) 1.000
Negative 3/45 (6.7) 3/42 (7.1) 6/87 (6.9)
Positive 40/45 (88.9) 39/42 (92.9) 79/87 (90.8)
High-risk HPV status 0.4315
Positive 38/40 (95.0) 35/39 (89.7) 73/79 (92.4)
Negative 2/40 (5.0) 4/39 (10.6) 14/79 (7.6)
HPV16 status 0.4826
Positive 14/38 (36.8) 16/35 (45.7) 30/73 (41.1)
Negative 24/38 (63.2) 19/35 (54.3) 43/73 (58.9)
HPV18 status 0.7125
Positive 5/38 (13.2) 3/35 (8.6) 8/73 (11.0)
Negative 33/38 (86.8) 32/35 (91.4) 65/73 (89.0)
Low-risk HPV status 0.4978
Positive 15/40 (37.5) 18/39 (46.2) 33/79 (41.7)
Negative 25/40 (62.5) 21/39 (53.8) 46/79 (58.3)
Number of HPV subtypes 0.4823
Single 16/40 (40.0) 12/39 (30.8) 28/79 (35.4)
Two or more 24/40 (60.0) 27/39 (69.2) 51/79 (64.6)
Unknown 2/45 (4.4) 0/42 (0) 2/87 (2.3)
The p-values represented are two-tailed Fisher’s exact (if <5 observations in any group) and χ2 tests (where >5 observations in every group).
HIV human immunodeficiency virus, HSV herpes simplex virus, HPV human papillomavirus, SD standard deviation.
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Fig. 2 Heatmap to show vaginal microbiota composition at baseline (time= 0) according to disease outcomes between 0–12 and 0–24 month follow-
up. CST Community state type, CST I Lactobacillus crispatus-dominant, CST III Lactobacillus iners-dominant, CST IV Lactobacillus spp.-depleted, high diversity,
HPV human papillomavirus, VMB vaginal microbiota. Top 20 taxa shown, and all remaining taxa denoted as ‘other’.
OR (95% CI)
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1.00 (Reference group)
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1.00 (Reference group)
1.00 (Reference group)
1.00 (Reference group)
1.30 (0.06, 27.07)
4.94 (0.26, 94.86)
1.87 (0.40, 8.81)
4.25 (0.98, 18.50)
1.14 (0.32, 4.05)
3.85 (1.10, 13.43)
3.56 (1.32, 9.61)
2.85 (1.03, 7.92)
3.07 (0.55, 17.14)
1054321.510.50.3
CST 3
CST 4
CST 1
Follow-up 12–24 months
CST 3
CST 4
CST 1
Follow-up 0–24 months
CST 3
CST 4
CST 1
Follow-up 0–12 months
Follow-up 12–24 months
Follow-up 0–24 months
Follow-up 0–12 months
SPECIES
Lactobacillus-dominant
Lactobacillus spp. deplete
Lactobacillus-dominant
Lactobacillus spp. deplete
Lactobacillus-dominant
Lactobacillus spp. deplete
GENUS
Fig. 3 Odds ratios and 95% confidence intervals of the association between the vaginal microbiome at genera and species level with risk of CIN2 non-
regression (vs regression) at different follow-up timepoints (baseline to 0–12month; baseline to 0–24month; 12 to 12–24month). Odds ratios have
been adjusted for age, ethnicity, contraception, douching, smoking and HPV16 and 18 status. CI confidence interval, CST Community state type, CST I
Lactobacillus crispatus-dominant, CST III Lactobacillus iners-dominant, CST IV Lactobacillus spp.-depleted, high diversity, OR odds ratio.
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christensenii was significantly more abundant however, in the
12-month sample of women who did not regress at 24 months
compared to those who did (p= 0.037, Welch’s t-test,
unadjusted) (Supplementary Fig. 3d).
Vaginal microbiota composition and CIN2 disease clearance.
Time to clearance of CIN according to VMB composition at
genus level showed a trend towards slower clearance with a
Lactobacillus-depleted VMB (p= 0.078, Log-rank test, Fig. 6).
Women with CST IV at baseline had a tendency to regress slower
than those with either CST I or III (p= 0.1864, Log-rank test)
(Supplementary Fig. 4).
Sixty-three of the 87 women regressed within the 24-month
follow-up period. Examination of VMB composition in the
sample taken at the appointment immediately before and
immediately after regression did not identify any compositional
structures associated with either pre- or post-regression state, or a
propensity to switch between particular compositions (Fig. 7).
Markov chain modelling was used to exploring the probability
of switching CSTs within the same individual at 12 and 24 months
using all available VMB composition data (Table 3,
Supplementary Fig. 5). Regression of CIN2 at 12 months was
more likely to remain within CST IV (0.89), than remain in CST I
(0.64) or III (0.59). Conversely, the most stable CST in non-
regressors was CST I (0.75), compared to CST III (0.67) and IV
(0.69). The most frequently observed transition in regressors was
CST IV to CST III (0.32), compared to CST III to CST IV in non-
regressors (0.28). For the 12–24-month subgroup, analysis an
opposite trend was seen. CST I was the most stable VMB in
regressors and CST IV most stable in non-regressors, with the
most frequent transition seen between CST III to CST IV in
regressors (0.29), and CST I to CST III in non-regressors (0.38)
(Table 3, Supplementary Fig. 5).
Discussion
A frequent limitation of research investigating microbiota asso-
ciations with cancer development, is the lack of longitudinal
studies to help differentiate the impact of the microbiome on
clinical outcomes and disease status23. In this study, we investi-
gated the relationship between vaginal microbiota composition
and the fate of CIN2 in a highly novel cohort of 87 young, eth-
nically diverse North American women. Our results suggest that
Table 2 Outcomes according to VMB composition at 12- and 24-month follow-up at genus and species level.
Genus level
Regression Non-regression Total Unadjusted OR, 95% CI
(p-value)
Adjusted OR, 95% CI
(p-value)a
Follow-up 0–12 months
Lactobacillus-dominant 33/57 (57.9%) 24/57 (42.1%) 57/87 (65.5%) REF REF
Lactobacillus spp.-depleted 9/30 (30.0%) 21/30 (70.0%) 30/87 (34.5%) 3.21, 1.32–8.22 (0.015) 3.56, 1.31–9.60 (0.012)
Total 42/87 (48.3%) 45/87 (51.7%) 87/87 (100%)
Follow-up 0–24 months
Lactobacillus-dominant 45/57 (78.9%) 12/57 (21.1%) 57/87 (65.5%) REF REF
Lactobacillus spp.-depleted 18/30 (60.0%) 12/30 (40.0%) 30/87 (34.5%) 2.50, 0.95–6.59 (0.064) 2.85, 1.03–7.92 (0.045)
Total 63/87 (72.4%) 24/87 (27.6%) 87/87 (100%)
Follow-up 12–24 months
Lactobacillus-dominant 15/22 (68.2%) 7/22 (31.8%) 22/35 (88.0%) REF REF
Lactobacillus spp.-depleted 6/13 (46.2%) 7/13 (53.8%) 13/35 (22.0%) 2.50, 0.61–10.26 (0.203) 3.06, 0.54–17.14 (0.202)
Total 21/35 (60.0%) 14/35 (40.0%) 35/35 (100%)
Species level
Regression Non-regression Total Unadjusted OR, 95% CI
(p-value)
Adjusted OR, 95% CI
(p-value)a
Follow-up 0–12 months
CST I 13/21 (59.1%) 8/21 (40.9%) 21/87 (24.1%) REF REF
CST III 20/36 (55.6%) 16/36 (44.4%) 36/87 (41.4%) 1.30, 0.43–3.90 (0.640) 1.14, 0.32–4.05 (0.838)
CST IV 9/30 (31.0%) 21/30 (69.0%) 30/87 (34.5%) 3.79, 1.17–12.30 (0.026) 3.85, 1.10–13.42, (0.035)
Total 42/87 (48.3%) 45/87 (51.7%) 87/87 (100%)
Follow-up 0–24 months
CST I 18/21 (85.7%) 3/21 (14.3%) 21/87 (24.1%) REF REF
CST III 27/36 (75.0%) 9/36 (25.0%) 36/87 (41.4%) 2.00, 0.47–8.41 (0.344) 1.86, 0.39–8.81 (0.432)
CST IV 18/30 (60.0%) 12/30 (40.0%) 30/87 (34.5%) 4.00, 0.96–16.61 (0.056) 4.25, 0.98–18.50 (0.054)
Total 63/87 (72.4%) 24/87 (27.6%) 87/87 (100%)
Follow-up 12–24 months
CST I 4/5 (80.0%) 1/5 (20.0%) 5/35 (14.3%) REF REF
CST III 11/16 (68.8%) 5/16 (31.2%) 16/35 (45.7%) 1.82, 0.15–20.71 (0.630) 1.30, 0.06–27.07 (0.865)
CST IV 6/13 (46.2%) 7/13 (53.8%) 13/35 (37.1%) 4.67, 0.40–53.95 (0.217) 4.94, 0.26–94.86 (0.29)
CST V 0/1 (0%) 1/1 (100%) 1/35 (2.9%) NAb NAb
Total 21/35 (60.0%) 14/35 (40.0%) 35/35 (100%)
Odds ratios (OR) are represented as unadjusted and adjusted for patient age, ethnicity, smoking, douching, contraception, HPV16 and 18 positivity, with p-values represented are two-tailed Fisher’s exact (if
<5 observations in any group) and χ2 tests (where >5 observations in every group).
aOR adjusted odds ratio, CI confidence Interval, CST community state type, CST I (Lactobacillus crispatus-dominant), CST III (Lactobacillus iners-dominant), CST IV (Lactobacillus spp.-depleted, high diversity),
CST V (Lactobacillus jensenii), NA not applicable, OR odds ratio, REF reference population.
aAdjusted odds ratio and 95% confidence intervals were calculated using Lactobacillus-dominant (genus) or CST I (species) as a reference group and adjusted for patient age, ethnicity, smoking, douching,
contraception, HPV16 and 18 positivity.
bIt was not possible to compute the OR, 95% CI and p-value for CST V compared to CST I.
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the composition of the vaginal microbiota at the time of CIN2
diagnosis may influence the natural history of CIN2. Lactobacillus
depletion and the presence of specific anaerobic species at the
time of CIN2 diagnosis was associated with significantly lower
chance of regression at 12- and 24-month follow-up. When
regression did occur in these women, it tended to do so at a
slower rate than in the presence of a Lactobacillus-dominant
VMB. A similar trend was seen between VMB composition at
12 months in women with persistent disease at this time and
clinical outcomes at 24 months, however reduced numbers of
women maintaining disease persistence at 12 months limited the
statistical power of this sub-analysis.
Temporal dynamics of VMB composition24, can be modulated
by endogenous (e.g. hormonal changes associated with menses)
and exogenous factors (e.g. contraception, sexual intercourse,
hygiene practices)24–26. It is therefore striking that VMB com-
position at baseline associates with CIN2 regression or non-
regression 12 and 24 months later, suggesting long-term inter-
action between vaginal bacterial composition and CIN2 natural
history, however further studies on more densely sampled women
would be required to elucidate this further.
Vaginal Lactobacillus spp. prevent colonisation of bacterial
vaginosis-associated bacterial species through maintenance of a
low pH27–30 and bacteriocin production31–33. An acidic envir-
onment can inhibit growth of several potentially pathogenic
species, such as Chlamydia trachomatis, Neisseria gonorrhoeae
and Gardnerella vaginalis27–30, yet provides optimal support for
cellular metabolic function of the cervix and the vagina34. This
feature is important for maintenance of the cervical epithelial
barrier function preventing HPV access to the basal keratino-
cytes35. When strict anaerobes are able to colonise, they produce
enzymes and metabolites, which may compromise this barrier,
facilitating HPV entry35. They also act on several cellular path-
ways that have been associated with increased levels of proin-
flammatory cervical cytokines36–39 that may enable a persistent,
productive viral infection and subsequent disease development
and progression40–44 on a background of chronic inflammation,
which is well-documented to promote neoplasia45. A recent
systematic review and network meta-analysis of VMB composi-
tion and HPV status has shown that a Lactobacillus spp. deplete
VMB is significantly associated with HPV infection compared to
a CST I state (OR 4.73 (95% CI 2.06–10.86))46. CST IV and CST
III have both previously been associated with increased acquisi-
tion and persistence of HPV infection in a 16-week longitudinal
study of sexually active women who were not known to have
cervical disease11. Other studies have associated specific bacterial
taxa such as Gardnerella, Atopobium and Megasphera to be
associated with HPV persistence11,47, which were also highlighted
as biomarkers of disease persistence in our cohort. Although
BVAB1 has not previously been associated with HPV or cervical
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Fig. 4 Outcomes at 12-month follow-up according to baseline VMB composition at baseline. A Lactobacillus spp.-depleted VMB (a) and CST IV (b) were
associated with significantly lower rates of regression compared to non-regression at 12 months. Significantly higher species richness (species observed)
was seen in women who had not regressed at 12 months follow-up (p= 0.0091), with diversity (Inverse Simpson index) also increased but this was not
significant (c). The baseline vaginal microbiota of women who did not regress at 12 months was characterised by an increased abundance of Megasphaera
(unclassified) (p= 0.0038, q= 0.081), Prevotella timonensis (p= 0.015, q= 0.153), Gardnerella vaginalis (p= 0.036, q= 0.252) and BVAB1 (p= 0.043, q=
0.228) (d). Data are represented as percentages in a, b and c as mean ± standard error of mean in d. The p-values by two-tailed unpaired t-test in c, and by
Welch’s t-test in d. Dots in c and d depict individual patients. (n= 87, ***p < 0.001; **p < 0.01; *p < 0.05). Source data are supplied as a Source Data File.
CST I Lactobacillus crispatus-dominant, CST III Lactobacillus iners-dominant, CST IV Lactobacillus spp.-depleted, high diversity.
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disease to our knowledge, it is commonly found in a bacterial
vaginosis state, and particularly associates with persistence after
antibiotic treatment, and has been suggested to increase risk of
HIV acquisition48.
We did not observe any particular association between VMB
composition at the time of clearance; either immediately before or
immediately after, or between a switch to one particular VMB
composition after clearance. However, there is likely to be a subtly
different temporality between clearance of HPV infection and
clearance of any resultant CIN.
Although a control population permitting comparison of
average VMB composition was not available, we observed com-
paratively high rates of CST III and CST IV, and lower rates of
CST I than were seen in our previously described cohort of
women with CIN14. Ethnicity has been demonstrated to influence
VMB composition49, and it is pertinent to note that this group
was made up of a more ethnically diverse group compared to our
previously described population which was predominantly Cau-
casian14. The higher rates of CST III and IV may also be
explained by the relatively high-risk sexual behavioural char-
acteristics of the women described in this study and as evidenced
by higher rates of previous Chlamydia trachomatis infection,
pregnancy and anal intercourse compared to the US general
population at the time of recruitment50, as well as compared to a
control population without cervical disease51. Sexual intercourse
in the absence of barrier protection is known to have an impact
on the composition and stability of the vaginal microbiota, and
was shown to increase the risk of Gardnerella vaginalis and L.
iners colonisation in a longitudinal study of 52 sexually active
women52, and to result in reduced abundance of L. crispatus53.
These data support a mechanism that puts these women at higher
risk of HPV acquisition, persistence and disease development.
However, we did not observe any significant differences in VMB
composition according to HPV status, although women with
HPV18 were more likely to have CST IV compared to those
ba
Non-regression
Regression
a: Atopobium_vaginae
b: Atopobium
c: Coriobacteriaceae
d: Prevotella_cluster2
e: Prevotella_timonensis
f: Prevotella
g: Prevotellaceae
h: Lactobacillus
i: Lactobacillaceae
j: Parvimonas_unclassified
k: Parvimonas
I: Clostridiales_IncertaeSedis
m: BVAB1
n: Lachnospiraceae_genus
o: Lachnospiraceae
p: Megasphaera_unclassified
q: Megasphaera
r: Veillonellaceae
s: Sneathia
t: Leptotrichiaceae
u: Species_other
v: Genus_other –6.0 –4.8 –3.6 –2.4 –1.2 0.0
LDA SCORE (log 10)
1.2 2.4 3.6 4.8 6.0
w: Family_other
Lactobacillales
Prevotella_timonensis
Prevotella_cluster2
Species_other
Genus_other
Class_other
Phylum_other
Family_other
Order_other
Parvimonas_unclassified
Negativicutes
Selenomonadales
Coriobacteriales
Clostridiales_IncertaeSedisXI
Atopobium
Atopobium_vaginae
Coriobacteriaceae
Fusobacteria
Sneathia
Leptotrichiaceae
Veillonellaceae
Megasphaera
Fusobacteriia
Megasphaera_unclassified
Fusobacteriales
Parvimonas
Lachnospiraceae_genus
Clostridiales
BVAB1
Clostridia
Lachnospiraceae
Prevotella
Bacteroidetes
Bacteroidia
Prevotellaceae
Bacteroidales
Actinobacteria
Actinobacteria
Lactobacillus
Firmicutes
Lactobacillaceae
Bacilli
Fig. 5 LEfSe analysis identified baseline vaginal microbiota biomarkers associated with clinical outcomes at 12 months follow-up. a Cladogram
representing taxa at all phylogenetic levels with significantly different abundance according to clinical outcome at 12-month follow-up. The size of the circle
is proportional to the abundance of taxon represented. b Histogram of LDA scores found to differ significantly in abundance between those who regressed
compared to those who did not regress. LDA linear discriminant analysis. Analysis restricted to top 20 taxa with all remaining taxa denoted as ‘other’.
100
50
0
0 10 20
Months elapsed
P
at
ie
nt
s 
w
ith
 C
IN
Lactobacillus spp.-dominant VMB
Lactobacillus spp.-deplete VMB
Fig. 6 Time to clearance of CIN according to baseline VMB composition
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infected with other subtypes, yet this was not significant and may
be a result of a relatively modest sample size.
Aside from environmental factors that may shift the VMB
composition, there is emerging data to suggest that the host
genetics also plays a role in determining microbiota
composition12,54. Markov modelling showed that irrespective of
whether CIN regressed, the VMB composition was relatively
stable, which suggest that it is not the CIN itself that dictates the
composition of the microbial environment. However, our results
are suggestive that the VMB may drive the outcome of the disease
and indicate an inverse relationship between strict anaerobes and
regression. This observation is consistent with a cross-sectional
cohort of women with cervical disease previously described by Oh
et al.13 who included women with LSIL or HSIL on cytology vs
normal controls (defined as normal or Atypical Squamous Cells
of Undetermined significance (ASCUS) cytology). They con-
cluded that microbiota patterns, characterised by low levels of L.
crispatus and occupied predominantly by A. vaginae and
secondarily by G. vaginalis and L. iners, were associated by an
almost 6-fold increase in the risk of cervical LSIL/HSIL disease
(higher vs lower tertile, odds ratio (OR) 5.80, 95% CI 1.73‒19.4),
compared to normal and thus the authors defined this as a ‘risky
microbial pattern’13. These clinical data, in addition to the in vitro
studies mentioned above are clearly suggestive that Lactobacillus
spp. have a protective role and indicate that strict anaerobes have
an inflammatory impact on the cervicovaginal environment
possibly enabling viral entry and facilitating persistence of HPV,
which is necessary for subsequent high-grade disease, its persis-
tence and progression. The potential interplay between the VMB
and molecular pathways is further discussed in two recently
published review articles55,56.
Regression rates in this cohort were high, with 48.3% regres-
sing by 12 months, and 72.4% by 24-month follow-up. This is
much higher than many other described cohorts57, which is likely
due to the young age of the included patients, consistent with
other studies in young women7. Our provisional findings suggest
the interaction between the vaginal microbiota and natural his-
tory of CIN warrants further investigation, because it may be
possible in the future to use VMB composition as a marker to
identify women most at risk of persistence and progression, and
even further as a therapeutic target for a more protective VMB.
The use of oral probiotics therapies has been proven to modulate
the composition of the VMB as a treatment for bacterial
vaginosis58,59, and are a worthwhile avenue to explore for women
with a Lactobacillus-depleted VMB, in light of our findings that
suggest the VMB composition remains stable even after clearance
of CIN, because this bacterial population could put them at risk of
recurrence and other adverse health outcomes associated with
Lactobacillus depletion including HIV and STI acquisition, and
pregnancy complications such as preterm rupture of membranes
and preterm birth60–63.
There are several potential confounders and limitations of the
data presented in this study. Firstly, the act of taking a biopsy has
been suggested to influence the natural history of CIN. There is
some evidence to indicate that taking a biopsy may cause acute
inflammation, which has been suggested by some to increase the
chance of clearance64, however, this point has been debated by
others65. All patients had a biopsy at the initial visit because a
histological diagnosis of CIN2 was a prerequisite for inclusion in
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Fig. 7 Sankey diagram of VMB composition immediately pre- and post-regression. There was no significant difference in vaginal microbiota composition
at either genus (a) or species level (b) in the sample immediately before, and the sample immediately after regression, n= 63. CST Community state type,
CST I Lactobacillus crispatus-dominant, CST III Lactobacillus iners-dominant, CST IV Lactobacillus spp.-depleted, high diversity.
Table 3 Markov modelling to assess transition probabilities
of VMB dynamics among non-regressors and regressors at
0–12, 0–24 and 12–24 months.
From/ to Regression Non-Regression
0–12 months
CST I CST III CST IV CST I CST III CST IV
CST I 0.64 0.14 0.22 0.75 0.20 0.05
CST III 0.09 0.59 0.32 0.18 0.67 0.15
CST IV 0 0.17 0.83 0.03 0.28 0.69
0–24 months
CST I CST III CST IV CST I CST III CST IV
CST I 0.69 0.19 0.12 0.75 0.08 0.17
CST III 0.12 0.63 0.25 0.23 0.58 0.19
CST IV 0 0.20 0.80 0.05 0.38 0.57
12–24 months
CST I CST III CST IV CST I CST III CST IV
CST I 0.66 0.17 0.17 0.75 0 0.25
CST III 0.08 0.67 0.25 0.38 0.38 0.24
CST IV 0.14 0.29 0.57 0 0.14 0.86
CST Community state type
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the study cohort. The number of subsequent biopsies carried out
during follow-up ranged from 0 to 6, and therefore may represent
a confounding factor not only because the biopsy may alter the
natural history, but it also may uncover a higher number of cases
of high-grade disease that could be missed by the relatively low
sensitivity of cervical cytology66,67.
Furthermore, in this analysis we defined as regressors women
with two consecutive visits with negative cytology and/or negative
biopsy, whilst LSIL was considered persistent disease as pre-
viously published for the same cohort10. This is also in line with
definitions used in most reports exploring clinical outcomes in
women with untreated CIN2 lesions8. The terms regression and
persistence are not always interchangeable. Persistence often
equates persistence of a specific lesion and regression refers to the
absolute absence of the lesion. As our analysis focused on
regression, categorising LSIL/CIN1 as persistence is more con-
sistent with the initial design.
A further confounder to consider is that it is difficult to
ascertain how long a lesion has been present. HPV16 and to a
lesser extent the phylogenetically related subtypes HPV31, 33, 35,
52 and 58 are consistently associated with higher rates of per-
sistence and progression68, with HPV16 and 18, followed by the
aforementioned high-risk non-16/18 subtypes, most commonly
detected in cervical cancer cases69. This fact may be difficult to
control for due to the logistics of how and when to recruit
women. We were also unable to control for phase of the men-
strual cycle or antibiotic use which could impact VMB
composition58,70. Finally, we do not have a control cohort of
disease-free women for comparison. It is clear that these women
exhibit certain behavioural characteristics which could both alter
their VMB structure and also disease outcomes.
We conclude that an absence of Lactobacillus spp. and presence
of a diverse population of strict anaerobes at the time of CIN2
diagnosis at baseline is associated with a decreased probability of
subsequent regression of untreated CIN2 lesions in young women
at 12 and 24 months of surveillance. There are several plausible
mechanisms for how this may arise, largely related to the devel-
opment of a proinflammatory environment that may arise in the
presence of a strict anaerobic environment compared to one
dominated by Lactobacillus spp. These findings suggest that VMB
composition could be a useful microbiological predictive marker
of disease outcome in some women. This could be used for tai-
lored surveillance and for the selection of women diagnosed with
CIN2 that would benefit from treatment, whilst minimising over-
treatment of lesions destined to regress and associated repro-
ductive morbidity. Furthermore, this could help the development
of VMB modulation therapeutic targets with pre- or probiotics
that could be used for treatment and/or prevention. Future suf-
ficiently powered longitudinal cohorts to assess the capacity of
baseline microbiota composition to predict regression or pro-
gression are highly desirable and may enable the development of
predictive models that could be used for risk stratification to
guide clinical decision making.
Methods
Study population — inclusion and exclusion criteria. Adolescent and young
women between the ages of 16 to 26 years of age with histologically proven CIN2 at
entry to the study were recruited at one of 12 clinics in Kaiser Permanente,
Northern California, USA between 2002 and 2007 and managed conservatively
with four-monthly monitoring, rather than immediate excisional treatment as
described elsewhere10. Ethical approval was obtained from the Institutional Review
Boards of the University of California, San Francisco, and Kaiser Permanente,
Northern California. All patients gave written informed consent to participate, and
to maintain anonymity only basic clinical data relating to disease outcome has been
included in Supplementary Table 2 and 3. Further data is available upon request.
Exclusion criteria included current pregnancy, previous cervical treatment for CIN,
immunosuppression or plans to leave the area within the next three years. A
detailed medical history was taken at recruitment and at subsequent visits to
include information regarding sexual and substance use practices. Women without
a baseline sample were also excluded. Women were included irrespective of their
ethnicity, parity, smoking habits, phase in their cycle and use of contraception.
A mandatory biopsy was performed at the first visit to confirm CIN2 for study
entry. At subsequent visits, a cytology sample was collected and in addition, a
colposcopy was performed. During follow-up, biopsies were taken on clinical
grounds, i.e. suspicion of progression based on colposcopy. An exit biopsy was also
performed in all patients who attended their final visit and gave consent regardless
of clinical need. If the last visit was missed and no histology was available, cytology
was used. In cases where there was no visible lesion at the exit visit, this biopsy was
taken from the site of the previous CIN2. Histological classification of cervical
biopsies at baseline was performed by the local histopathologist and sent to the
centralised laboratory for verification by a second histopathologist. All other
biopsies obtained through-out the study were sent directly to centralised laboratory.
Examination and sample processing. A cervical sample using a cytobrush and
spatula was collected during each speculum examination and immediately placed
in PreservCyt solution (Hologic, Marlborough, MA, USA) as per routine collection
of a cervical smear. Samples were collected every 4–6 months during the 24 months
follow-up. Cervical cytology and HPV genotyping were performed within one week
on the PreservCyt fluid following sampling. The remaining PreservCyt sample was
frozen at −80 °C until the time of bacterial DNA extraction. Whole genomic
bacterial DNA was extracted from 500 μl of PreservCyt solution using a QIAmp
DNA Mini kit (Qiagen, Venlo, Netherlands) according to manufacturer’s
instructions. After the cervical sample collection, standard colposcopic examina-
tions were performed. If lesion appeared to progress, biopsies were taken.
HPV genotyping. HPV testing was performed using Roche LINEAR ARRAY®
HPV Genotyping Test, a qualitative test to detect 37 high- and low-risk HPV
genotypes (HPV-6, -11, -16, -18, -26, -31, -33, -35, -39, -40, -42, -45, -51, -52, -53,
-54, -55, -56, -58, -59, -61, -62, -64, -66, -67, -68, -69, -70, -71, -72, -73, -81, -82,
-83, -84 and -89)71.
Illumina MiSeq sequencing of 16S rRNA gene amplicons. The V1–V2 hyper-
variable regions of 16S rRNA genes were amplified for sequencing using forward
and reverse fusion primers. The forward primer consisted of an Illumina i5 adapter
(5′-AATGATACGGCGACCACCGAGATCTACAC-3′), an 8-base-pair (bp) bar
code, a primer pad (forward, 5′-TATGGTAATT-3′) and the 28F primer (5′-GAGT
TTGATCNTGGCTCAG-3′). The reverse fusion primer was constructed with an
Illumina i7 adapter (5′-CAAGCAGAAGACGGCATACGAGAT-3′), an 8-bp bar
code, a primer pad (reverse, 5′-AGTCAGTCAG-3′) and the 388R primer (5′-TGC
TGCCTCCCGTAGGAGT-3′). Sequencing was performed at RTL Genomics
(Lubbock, TX, USA) using an Illumina MiSeq platform (Illumina Inc).
16S rRNA gene sequence analysis. Sequence data was processed in Mothur using
the MiSeq SOP Pipeline72. Sequence reads were quality checked and normalised to
the lowest number of reads. Singleton operational taxonomic units (OTUs) and
OTUs <10 reads in any sample were collated into OTU_singletons and OTU_rare
phylotypes respectively, to maintain normalisation and to minimise artefacts. OTUs
were defined using a cut-off value of 97% and result data analysed using Vegan
package within the R statistical package for assessment of microbial composition
and diversity (R Development Core Team 2008). OTU taxonomies (from Phylum to
Genus) were determined using the ribosomal database project (RDP) MultiClassifier
script to generate the RDP taxonomy73, whereas species level taxonomies of the
OTUs were determined using the USEARCH algorithm (v.11) combined with the
cultured representatives from the RDP74 and STIRRUPS databases75. Alpha and
beta indices were calculated from these datasets within Mothur and the Vegan
package with the R environment (R Development Core Team 2008)76.
Statistical analysis. Regression of CIN2 was defined as negative cytology and/or
negative biopsy in two consecutive visits and no further cytological or histological
abnormality during follow-up. Histology was used in preference to cytology; if not
available, cytology was used. If the patient was lost to follow-up after a single
negative cytology, the analysis was censored for the result of the last abnormal
cytology or histology. Non-regression was used to define anyone with either (a)
persistence; the continuing presence of low- or high-grade abnormal cytology and/
or CIN1 to CIN2 on histology, if available or (b) progression; biopsy-proven CIN3
at any follow-up visit.
Analysis of statistical differences between the vaginal microbiota of samples
according to disease outcome was performed using the Statistical Analysis of
Metagenomic Profiles (STAMP) package (v.2.1.3)77. Data were subjected to
multivariate analysis using hierarchical clustering analysis (HCA) by centroid
clustering with a density threshold of 0.75. Vaginal microbiota composition was
classified initially into two groups at genus level according relative abundance of
Lactobacillus; Lactobacillus-dominant or Lactobacillus-depleted. Species level data
was then used to classify samples into groups analogous to previously described
vaginal community state types (CSTs) I–V49. VMB composition at the baseline
visit was compared at genus and species level according to whether women were
classified as regressors or non-regressors at 12 and 24 months. We calculated odds
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ratios (ORs) and 95% confidence intervals (95% CI) and p-values to explore
significance using 3. We further performed a logistic regression model to adjust for
known confounders (age, ethnicity, contraception, smoking, douching practice and
HPV16 and 18 status) and calculated adjusted OR (aOR), using Fisher’s exact and
χ2 tests; adjusted ORs were reported in preferences to unadjusted. A further
subgroup analysis was performed that included women who had not regressed
12 months into the study. Their VMB composition on the day of their 12-month
follow-up appointment was considered a new baseline, and the outcome 12 months
later (24 months since study enrolment) was observed according to the 12-month
VMB composition, using these same analytical techniques. The analyses were
performed in STATA statistical software (v.14).
Welch’s t-test was used to perform compare relative abundance of specific
species according to clinical outcomes. Linear discriminant analysis (LDA) effect
size (LEfSe) analysis was used to identify taxa significantly overrepresented
according to clinical outcome, through all taxonomic levels78. This analysis was
performed using taxonomic relative abundance, with per-sample normalisation
and default settings for alpha values (0.05) for the factorial Kruskal–Wallis test
among classes and pairwise Wilcoxon test between subclasses. A logarithmic LDA
score >2 was used to determine discriminative features.
Comparison of the VMB dynamics and stability among non-regressors and
regressors at 12 and 24 months were analysed based on microbial CST transitions
using Markov modelling79. Individuals were censored from this analysis once they
regressed. Other statistical analyses were performed using the statistical package
GraphPad Prism v.8.0.1 (GraphPad Software Inc., California, USA). A p-value less
than 0.05 was considered statistically significant.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Sequence data that support the findings of this study have been deposited in the
European Nucleotide Archive’s (ENA) Sequence Read Archive (SRA) repository; https://
www.ncbi.nlm.nih.gov/sra with the accession code PRJEB31832. Basic metadata relating
to disease outcome is available in Supplementary Tables 2 and 3 to use alongside this to
maintain anonymity. Further metadata is available upon request, however at the time of
recruitment, we did not seek explicit permission to openly release all clinical data in a
data repository. The source data underlying Figs. 4–6 and Supplementary Figs. 2–4 are
provided as a Source Data file.
Code availability
Markov modelling was performed using a custom R code, which has been deposited in
the GitHub repository; https://github.com/anitamitra/Markov/tree/V1.0.
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